October 17 – 19 2017 | Boston, MA

Hyatt Regency Boston

Day 1
Wednesday October 19th, 2016

Day 2
Thursday October 20th, 2016

Day 3
Friday October 21st, 2016

Tuesday October 18th, 2016


We’re busy building the agenda for 2017

Register your interest here for the latest updates on World CDx Boston 2017.


Register Your Interest



Registration for Workshop A & Coffee

Workshop A – Addressing the Challenges to Commercial Success for your CDx


Hosted by ANGLE plc in collaboration with the DxMA

Time: 9.00am-1.00pm

Purpose – Understanding the challenges in building a successful commercialization strategy will be explored in this workshop:

  • Gain a deep understanding of the U.S. and key global market access and reimbursement landscapes to inform robust strategic decision making
  • Detailed insight into how organizations have successfully developed partnerships enabling smooth commercialization and market adoption
  • In-depth discussion around how to continue to secure regulatory approvals

Workshop Agenda

9:00 Workshop Overview – Peggy Robinson

9:10 Overview of Global Market Access and Reimbursement Landscape with a Focus on US

9:40 The Global Regulatory Horizon & Partnership Components – “How to build a good marriage?”

10:10 Short Break

10:30 The Health Economics of CDx

11:00 Dx Stakeholder Perspective

11:30 CRO/Lab Stakeholder Perspective

12:00 Panel Discussion – An interactive discussion with a multistakeholder panellists experienced in enabling smooth commercialization and market adoption

Workshop Led by ANGLE plc in collaboration with DxMA:

  • Peggy Robinson, US Vice President, ANGLE plc
  • Lawrence J. Worden, President, DxMA and Managing Partner, MDxI
  • Bill Pignato, Founder and Principal at W.J. Pignato & Associates, LLC
  • Steven Anderson, CSO, Covance
  • Kathryn Becker, Franchise Director, Oncology and Companion Diagnostics, Abbott Molecular
  • Paul Keeling, CEO Diaceutics
  • Charles Matthews, VP, Boston Healthcare

Registration for Workshop B & Networking Lunch

Workshop B – Comprehensive Understanding of the CDx Development Process From Biomarker Discovery to Approved & Marketed CDx Product


Hosted by Hologic

Time: 2.00pm-6.00pm

Purpose – In depth insight into the needs of both pharmaceutical and diagnostic companies as well as global regulatory agencies and reimbursement

  • A comprehensive understanding of the CDx development process from biomarker discovery to approved and marketed CDx product
  • Understanding the Rx-Dx Dynamic
  • Embarking Down the CDx Road: When, Where & How?
  • Clinical & Regulatory Challenges

14.00 Welcome Introduction and Ice Breaker

14.10 CDx Development From the Rx and Dx Perspective

14.50 Interactive Solution Finding – Better Understanding the Evolving Rx-Dx Dynamic

15.05 Refreshment & Coffee Break

15.30 How does Pharma choose projects for CDx development and how to partner with a Dx company to enable success?

15.50 Where and how does regulatory and its route affect CDx development?

16.20 Interactive Solution Finding – Embarking Down the CDx Road: When, Where & How?

16.40 Short Comfort Break

16.50 Understanding Interactions with the FDA

17.20 Reimbursement challenges for a Dx Company in a CDx Area

17.40 Interactive Solution Finding – Overcoming Clinical and Regulatory Challenges

18.00 Closing Remarks of Workshop

Workshop Led by Hologic:

  • Dr Bob Holt, Companion Diagnostic Development Manager, Hologic
  • Paul Docherty, Regional Sales Manager, Hologic
  • Jane Kelly, Biomarker Services Operations Manager, Hologic
  • anice Hogan, Partner, Hogan Lovells US LLP
  • Martin Armstrong, Senior Director of Molecular Genetics, UCB Pharma
  • Paul Radensky, Partner, McDermott, Will & Emery

Evening Drinks Reception Co-Hosted by ANGLE & Hologic